Skip to content
Clinical Trials – home

Osteoporosis Diagnostics

6 / 10 trials open to patients6 countries

In short

Osteoporosis is often called a "silent disease" because it weakens bones without causing any obvious symptoms until a fracture happens. Many people discover they have osteoporosis only after breaking a bone from a minor fall or bump. Early detection through proper diagnostic testing can make a significant difference in preventing painful fractures and protecting your long-term health and independence.

Key points

  • Osteoporosis is truly silent—most people have absolutely no symptoms until they suddenly break a bone from a minor fall or accident.
  • All women age 65 and older should get screened with a DEXA scan, even if they feel perfectly healthy and have no symptoms.
  • Breaking a bone after age 50 is a red flag that should never be ignored—it often signals that osteoporosis is already weakening your skeleton.
  • A DEXA scan is quick, painless, and uses less radiation than a regular chest x-ray, making it one of the safest diagnostic tests available.
  • Your T-score from a bone density test is the critical number—below -2.5 means you have osteoporosis, while -1 to -2.5 indicates osteopenia (early bone loss).
  • Having one fracture dramatically increases your risk of another within the next year, making early diagnosis and treatment absolutely essential.
  • Many spine fractures from osteoporosis happen without any pain at all, so you could have broken vertebrae right now and not even know it.
  • Clinical trials for osteoporosis use sophisticated diagnostic tests to carefully monitor bone changes and help develop better treatments for future patients.

Introduction: Who Should Seek Osteoporosis Diagnostics

Osteoporosis develops slowly over many years, usually without any warning signs or symptoms that you can feel or notice. Because this condition weakens bones gradually and silently, most people have no idea they have it until something serious happens—like breaking a bone from a simple fall or even a cough. This is why understanding when to seek diagnostic testing is so important for protecting your bone health.

If you are a woman age 65 or older, you should talk to your healthcare provider about getting screened for osteoporosis. The screening recommendations are clear: all women in this age group should be tested, even if they feel perfectly healthy. For postmenopausal women under age 65, screening becomes important if you have certain risk factors that increase your chances of developing osteoporosis or experiencing a fracture. Men should also consider screening, especially if they are over 70 years old or have specific risk factors, although guidelines for men are still being refined.

You should seek diagnostic testing sooner if you went through early menopause (before age 45) or had your ovaries surgically removed. These situations cause a sharp drop in estrogen levels, which is a hormone that helps protect bone density. If you have taken high-dose steroid medications (called corticosteroids) for more than three months, you are also at higher risk because these medications can weaken bones over time.

Having a parent or sibling with osteoporosis—especially if they experienced a hip fracture—is another important reason to seek testing. Family history plays a significant role in determining your own risk. If you have broken a bone after age 50 from what seems like a minor accident, such as falling from standing height or less, this is a strong signal that you need diagnostic evaluation. Such breaks are called fragility fractures, and they often indicate that osteoporosis is already present.

Other situations that should prompt you to seek diagnostic testing include having a low body weight or small body frame, experiencing unexplained height loss (losing an inch or more), developing a hunched or stooped posture, or having long-term back pain. Certain medical conditions—such as rheumatoid arthritis, kidney disease, overactive thyroid, digestive disorders that affect nutrient absorption, or eating disorders—also increase your risk and make testing advisable.

If you take medications known to affect bone health, such as antiepileptic drugs, certain cancer treatments, medications for acid reflux (proton pump inhibitors), or thyroid hormone replacement at high doses, you should discuss bone density testing with your provider. Lifestyle factors like smoking, heavy alcohol use, or long periods of physical inactivity also contribute to bone loss and warrant earlier screening.

Classic Diagnostic Methods for Identifying Osteoporosis

The process of diagnosing osteoporosis typically begins with your healthcare provider taking a detailed medical history and asking about factors that might affect your bone health. They will want to know about any previous fractures, your family history, the medications you take, your diet and exercise habits, and whether you smoke or drink alcohol. This conversation helps them understand your overall risk profile and determine whether testing is needed.

During a physical examination, your provider may check for specific signs that could suggest bone loss. They might measure your height carefully and compare it to previous measurements, because losing height over time can indicate that bones in your spine have collapsed or become compressed. They may also observe your posture to see if you have developed a forward stoop or hunch, which happens when weakened vertebrae can no longer support the weight of your body properly. Checking your balance, the way you walk (called gait), and your muscle strength helps them assess your risk of falling and breaking a bone.

The main and most reliable diagnostic tool for osteoporosis is a bone density scan, also called a DEXA scan (which stands for dual-energy x-ray absorptiometry). This test measures how much mineral is packed into your bones, which tells doctors how strong or weak they are. The DEXA scan is painless and quick, usually taking only 10 to 20 minutes. You simply lie still on a padded table while a scanner passes over your body, typically focusing on your hip and spine because these are the areas most commonly affected by osteoporosis and most likely to fracture.

The DEXA scan uses very low levels of x-rays—much less radiation than a regular chest x-ray—so it is considered very safe. You don't need any special preparation for the test, though you may be asked to avoid taking calcium supplements for a day or two beforehand and to wear loose, comfortable clothing without metal buttons or zippers.

After the scan, your results are reported as a T-score. This is a number that compares your bone density to the average bone density of a healthy young adult of the same sex and race, typically someone in their mid-20s when bone mass is at its peak. Understanding your T-score is straightforward. If your T-score is above -1, your bone density is considered normal. If your T-score falls between -1 and -2.5, you have reduced bone density, which is called osteopenia. This is not yet osteoporosis, but it means you are at higher risk of developing it. If your T-score is -2.5 or lower, you have osteoporosis. The lower the number, the weaker your bones are and the higher your risk of fracture.

In addition to the DEXA scan, your provider may use an online risk assessment tool to estimate your likelihood of breaking a bone in the next 10 years. Two commonly used tools are called FRAX and Q-Fracture. These calculators take into account your age, sex, weight, height, previous fractures, family history, lifestyle factors, and other health conditions to give a more complete picture of your fracture risk. This information helps your provider decide whether treatment is necessary and how aggressive that treatment should be.

Sometimes osteoporosis is discovered by accident when you have an x-ray for another reason, such as a chest x-ray or an x-ray after an injury. Regular x-rays can show if bones have already become significantly thinned or if you have vertebral fractures in your spine that you might not have even known about. Many spine fractures from osteoporosis don't cause immediate pain, so they go unnoticed until an x-ray reveals them. These are called asymptomatic vertebral fractures, and finding them is important because they indicate that osteoporosis is already causing damage.

If your initial test results are abnormal or if your provider suspects that another condition might be causing your bone loss (called secondary osteoporosis), they may order blood tests or urine tests. These lab tests can check for problems with your thyroid, parathyroid glands, kidneys, or liver. They can measure your calcium and vitamin D levels, check for hormonal imbalances, or look for signs of other diseases that affect bones. A 24-hour urine collection might be done to see how much calcium your body is losing through urine.

In certain cases, especially when the diagnosis is unclear or when your provider suspects a rare bone disease, they might recommend more advanced imaging tests. A CT scan (computed tomography) can provide detailed pictures of your bones and help assess fractures more precisely. An MRI scan (magnetic resonance imaging) uses magnets and radio waves to create detailed images of soft tissues and bones, which can be helpful for identifying subtle fractures or other bone problems that don't show up clearly on regular x-rays.

Diagnostics for Clinical Trial Qualification

Clinical trials studying new treatments for osteoporosis have specific requirements for who can participate. Understanding these diagnostic standards helps researchers ensure they are studying the right group of people and that their results will be meaningful and reliable. If you are considering joining a clinical trial for osteoporosis, you will likely go through a thorough evaluation process.

The most important diagnostic test used to qualify patients for osteoporosis clinical trials is the DEXA scan. Trial organizers need precise measurements of your bone density at the start of the study so they can accurately track any changes that happen during treatment. Most clinical trials require participants to have a T-score of -2.5 or lower at the hip or spine to confirm that osteoporosis is present. Some trials may accept participants with osteopenia (T-scores between -1 and -2.5) if they also have other high-risk factors, such as a previous fragility fracture or a strong family history.

In addition to confirming bone density levels, clinical trials often require documentation of your medical history to verify that you meet specific inclusion criteria. For example, trials studying treatments for postmenopausal osteoporosis will confirm that you have gone through menopause, which may involve checking hormone levels in your blood. Trials focusing on osteoporosis caused by steroid medications will require proof that you have been taking corticosteroids for a certain period of time.

Blood tests and urine tests are commonly required as part of the screening process for clinical trials. These tests serve multiple purposes. They help rule out other medical conditions that might affect bone health or interfere with the study treatment. They establish baseline values for important markers of bone health, such as calcium, vitamin D, and specific proteins that indicate bone turnover (how fast your body is breaking down and rebuilding bone). Researchers use these baseline measurements to monitor your response to treatment throughout the study.

Some clinical trials may also require x-rays of your spine to look for existing vertebral fractures. The presence or absence of previous fractures helps researchers classify participants into different risk groups and allows them to study whether a new treatment can prevent new fractures in people who have already experienced bone breaks. X-rays taken at the beginning and end of a trial can also help researchers count and compare the number of new fractures that occur in people receiving the experimental treatment versus those receiving a placebo or standard treatment.

Clinical trials frequently use specialized blood or urine tests to measure bone turnover markers. These are substances released into your bloodstream or urine as your bones break down and rebuild. Examples include substances with names like C-telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP). Although these tests are not typically used to diagnose osteoporosis in regular clinical practice, they are valuable research tools because they can detect changes in bone metabolism more quickly than bone density scans can. This helps researchers see whether a new treatment is working even before changes in bone density become apparent.

Before you can be enrolled in a clinical trial, the research team will review all your diagnostic test results to make sure you are a good candidate. They will check that you meet all the inclusion criteria (the specific characteristics required to participate) and that you don't have any exclusion criteria (factors that would make participation unsafe or would interfere with the study results). This might include checking that your kidney and liver function are adequate, that you don't have certain other bone diseases, and that you're not taking medications that would conflict with the study treatment.

Some advanced clinical trials might use additional imaging techniques beyond standard DEXA scans. For example, some studies use specialized CT scans that measure bone density in three dimensions, providing even more detailed information about bone quality and structure. Others might use a technique called quantitative ultrasound, which uses sound waves to assess bone properties without radiation exposure. These advanced techniques are primarily research tools and are not commonly used in routine clinical practice.

Throughout the clinical trial, you will likely have repeat diagnostic tests at scheduled intervals—perhaps every 6 months or once a year—to track changes in your bone density and overall health. These follow-up tests are essential for determining whether the experimental treatment is effective and safe. Your participation in these regular assessments contributes valuable information to medical science and helps researchers develop better treatments for osteoporosis that may benefit millions of people in the future.

Prognosis and Survival Rate

Prognosis

Osteoporosis itself is not a terminal or life-threatening disease, but it significantly affects quality of life and can lead to serious complications through fractures. The outlook for someone with osteoporosis depends largely on whether they experience fractures and how severe those fractures are. With early diagnosis and proper treatment, many people with osteoporosis can maintain good bone health and avoid fractures entirely.

The most serious concern with osteoporosis is hip fractures. These injuries can have profound effects on a person's independence and overall health. About twenty percent of seniors who break a hip die within one year from complications related to either the broken bone itself or the surgery needed to repair it. These complications can include blood clots, pneumonia, or other problems that arise from prolonged immobility during recovery. Many people who survive hip fractures never fully regain their previous level of mobility and may require long-term nursing home care.

Spinal fractures from osteoporosis are the most common type of osteoporotic fracture, yet many people don't even realize they have them because they can occur without obvious symptoms. When these fractures do cause problems, they often lead to chronic back pain, loss of height, and a stooped or hunched posture. Multiple spinal fractures can reduce lung capacity, leading to breathing difficulties. The good news is that not everyone with osteoporosis will break a bone, and those who don't experience fractures typically have no pain or long-term problems from the condition.

One of the most concerning aspects of osteoporosis prognosis is the increased risk of additional fractures after the first one. Having one fragility fracture dramatically increases your chances of having another. In fact, one in four women who have a new spine fracture will experience another fracture within just one year. This pattern of recurring fractures can create a downward spiral of disability, pain, and loss of independence.

The prognosis improves significantly with treatment. Medications and lifestyle changes can slow bone loss, improve bone density, and substantially reduce fracture risk. Studies show that osteoporosis treatments can reduce hip fractures by up to 40 percent and spinal fractures by 30 to 70 percent. The earlier osteoporosis is diagnosed and treatment begins, the better the chances of preventing fractures and maintaining quality of life. People who adhere to their treatment plans, engage in appropriate exercise, ensure adequate calcium and vitamin D intake, and take steps to prevent falls have much better outcomes than those who remain untreated.

Survival rate

Because osteoporosis itself is not a fatal disease, there is no specific survival rate associated with simply having the condition. However, the complications from osteoporotic fractures can affect mortality rates. As mentioned, approximately 20 percent of older adults who suffer hip fractures die within one year due to complications. This statistic highlights why prevention and early treatment of osteoporosis are so critical.

The vast majority of people diagnosed with osteoporosis live normal lifespans, especially if they receive appropriate treatment and avoid major fractures. Life expectancy is not directly reduced by osteoporosis when the disease is properly managed. The key to maintaining both longevity and quality of life with osteoporosis is preventing fractures through medication, lifestyle modifications, fall prevention strategies, and regular monitoring of bone health.

Did you know?

  1. About 80% of patients who break a bone are still not diagnosed or treated for osteoporosis even after the fracture, missing a critical opportunity to prevent future breaks.
  2. The radiation exposure from a DEXA scan is extremely low—about one-tenth the radiation dose of a standard chest x-ray, making it one of the safest imaging tests available.
  3. Many spine fractures from osteoporosis happen silently without any pain or obvious symptoms, and people only discover them accidentally during x-rays done for other reasons.

Questions people often ask

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Osteoporosis

Recruiting trials first

See all 10 trials →
Quick filters

10 clinical trials in this condition

Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Zoledronic Acid
  • Sponsor:AUVA Trauma Center Vienna

Osteoporosis

Recruiting
Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Alendronic Acid
  • Sponsor:Odense University Hospital

Osteoporosis

Recruiting
Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Zoledronic Acid
  • Sponsor:Region Midtjylland

Osteoporosis

Recruiting
Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Romosozumab
  • Sponsor:Region Midtjylland
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Denosumab
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Osteoporosis+1

Not yet recruiting
Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dasatinib
  • Sponsor:Odense University Hospital
See all 10 trials →filters applied: condition = Osteoporosis

Related conditions in the same therapeutic area

Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).